This episode of MENA MedTech Insights dives into the UAE's newly mandated digital post-market surveillance platform, SAWAD. We unpack the immediate technical and regulatory challenges facing medical device manufacturers, as the Ministry of Health and Prevention (MOHAP) moves to a fully centralized, data-driven vigilance system. This shift is more than a simple software update; it represents a new era of active compliance and data analysis in the region.

Imagine your company's critical post-market summary report for the UAE is suddenly rejected. The reason is not the quality of your data, but its format, which is incompatible with the new mandatory SAWAD platform's API. Your team is now scrambling to re-engineer its data export protocols against a tight compliance deadline, risking fines and potential market access disruption. This episode explores how to avoid this exact scenario.

Key questions answered in this episode:

- What are the specific technical requirements for integrating with the UAE's new SAWAD platform?

- Why is your existing global vigilance system likely not compliant with the new MOHAP rules?

- How does this new platform change the nature of adverse event reporting in the UAE?

- What specific data points are now required that go beyond standard international practice?

- Is this new regulation a barrier to entry or a long-term opportunity for proactive companies?

- How does the SAWAD platform fit into the UAE's broader digital health and Vision 2030 strategy?

- What are the immediate compliance risks for manufacturers who fail to adapt?

At Pure Global, we specialize in navigating these complex regulatory shifts. We offer end-to-end solutions combining local expertise with advanced AI tools to streamline your global market access, from initial registration to post-market surveillance. Don't let regulatory hurdles block your growth in key MENA markets. Contact us for a consultation at [email protected] or learn more by visiting https://pureglobal.com/.